ATE491022T1 - CONDITIONALLY IMMORTALIZED ADULT LONG-TERM STEM CELLS AND METHOD FOR THE PRODUCTION AND USE OF SUCH CELLS - Google Patents
CONDITIONALLY IMMORTALIZED ADULT LONG-TERM STEM CELLS AND METHOD FOR THE PRODUCTION AND USE OF SUCH CELLSInfo
- Publication number
- ATE491022T1 ATE491022T1 AT06826025T AT06826025T ATE491022T1 AT E491022 T1 ATE491022 T1 AT E491022T1 AT 06826025 T AT06826025 T AT 06826025T AT 06826025 T AT06826025 T AT 06826025T AT E491022 T1 ATE491022 T1 AT E491022T1
- Authority
- AT
- Austria
- Prior art keywords
- cells
- methods
- stem cells
- production
- conditionally immortalized
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 210000004027 cell Anatomy 0.000 title abstract 5
- 210000000130 stem cell Anatomy 0.000 title abstract 2
- 230000007774 longterm Effects 0.000 title 1
- 238000010172 mouse model Methods 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 210000004504 adult stem cell Anatomy 0.000 abstract 1
- 230000011712 cell development Effects 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001671 embryonic stem cell Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
Abstract
Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72813105P | 2005-10-18 | 2005-10-18 | |
US76599306P | 2006-02-06 | 2006-02-06 | |
PCT/US2006/040379 WO2007047583A2 (en) | 2005-10-18 | 2006-10-18 | Conditionally immortalized long-term stem cells and methods of making and using such cells |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE491022T1 true ATE491022T1 (en) | 2010-12-15 |
Family
ID=37963171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06826025T ATE491022T1 (en) | 2005-10-18 | 2006-10-18 | CONDITIONALLY IMMORTALIZED ADULT LONG-TERM STEM CELLS AND METHOD FOR THE PRODUCTION AND USE OF SUCH CELLS |
Country Status (13)
Country | Link |
---|---|
US (7) | US8883507B2 (en) |
EP (1) | EP1942739B1 (en) |
JP (8) | JP2009511081A (en) |
KR (2) | KR101441693B1 (en) |
CN (2) | CN105483088B (en) |
AT (1) | ATE491022T1 (en) |
AU (1) | AU2006304392B2 (en) |
CA (2) | CA2626525C (en) |
DE (1) | DE602006018768D1 (en) |
HK (2) | HK1126623A1 (en) |
IL (7) | IL296832A (en) |
IN (1) | IN2014DN06624A (en) |
WO (1) | WO2007047583A2 (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2626525C (en) * | 2005-10-18 | 2020-03-10 | National Jewish Medical And Research Center | Conditionally immortalized long-term stem cells and methods of making and using such cells |
PT2035549E (en) | 2006-05-31 | 2014-10-06 | Childrens Medical Center | Abcb5 positive mesenchymal stem cells as immunomodulators |
GB0619500D0 (en) * | 2006-10-03 | 2006-11-08 | Univ Keele | Treatment of fibrosis |
EP2583550A1 (en) | 2007-03-13 | 2013-04-24 | National Jewish Health | Methods for generation of antibodies |
KR20170078862A (en) | 2008-05-16 | 2017-07-07 | 타이가 바이오테크놀로지스, 인코포레이티드 | Antibodies and processes for preparing the same |
AU2009274172B2 (en) * | 2008-07-21 | 2015-08-13 | Htyr Acquisition Llc | Differentiated anucleated cells and method for preparing the same |
EP3339321B1 (en) * | 2008-08-28 | 2021-04-28 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same and methods of identifying agents that modulate myc |
US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
ES2796111T3 (en) | 2008-11-14 | 2020-11-25 | Brigham & Womens Hospital Inc | Therapeutic methods related to cancer stem cells |
DK2448967T3 (en) * | 2009-06-29 | 2015-07-20 | Ilya B Leskov | NON-HUMAN MAMMALS MODEL OF CANCER human hematopoietic |
AU2014240253B2 (en) * | 2009-09-15 | 2017-08-03 | The University Of Tokyo | Novel Method for Producing Differentiated Cells |
KR101667834B1 (en) * | 2009-09-15 | 2016-10-20 | 고쿠리츠다이가쿠호우진 도쿄다이가쿠 | Novel method for producing differentiated cells |
US20120321595A1 (en) * | 2009-11-09 | 2012-12-20 | The Brigham And Women's Hospital, Inc. | Treatment of heart disease |
JP2013528368A (en) * | 2010-05-06 | 2013-07-11 | ステム セル メディスン リミテッド | Stem cell bank for individual medical care |
WO2012043651A1 (en) * | 2010-09-30 | 2012-04-05 | 国立大学法人 熊本大学 | Production method for myeloid blood cells |
US8889630B2 (en) | 2011-12-23 | 2014-11-18 | Carlos Lopez | Method for hair regrowth using Granulocyte-Colony Stimulating Factor |
US20130171115A1 (en) * | 2011-12-30 | 2013-07-04 | Gang Li | Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene |
CN114645015A (en) * | 2012-07-20 | 2022-06-21 | 泰加生物工艺学公司 | Enhanced reconstitution and autoreconstitution of hematopoietic compartments |
AU2014219026B2 (en) | 2013-02-19 | 2018-11-29 | Children's Medical Center Corporation | ABCB5(+) stem cells for treating ocular disease |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
US11446331B2 (en) | 2013-05-10 | 2022-09-20 | The Brigham And Women's Hospital, Inc. | Wound healing and tissue engineering |
KR101638403B1 (en) * | 2013-07-17 | 2016-07-11 | 아주대학교산학협력단 | Media composition for inducing stem cell comprising replusive guadiance molecule c and method for inducing stem cell using the same |
WO2015020993A2 (en) * | 2013-08-05 | 2015-02-12 | The Trustees Of The University Of Pennsylvania | RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA |
CN103509101B (en) * | 2013-08-12 | 2016-11-02 | 中国科学院广州生物医药与健康研究院 | A kind of cytokine expanding umbilical cord blood hematopoietic stem cell and culture medium thereof |
WO2016149672A1 (en) | 2015-03-18 | 2016-09-22 | The Regents Of The University Of California | Methods of preventing and reversing stem cell aging |
CN106148266A (en) * | 2015-04-20 | 2016-11-23 | 烟台赛泽生物技术有限公司 | A kind of immunocyte culture medium and the additive of this culture medium |
CN104928247B (en) * | 2015-07-02 | 2018-03-23 | 广州赛莱拉干细胞科技股份有限公司 | A kind of nerve stem cell culture medium and NSC adhere-wall culture method |
EP3324982A4 (en) | 2015-07-21 | 2019-01-09 | The Children's Medical Center Corporation | Pd-l1 expressing hematopoietic stem cells and uses |
SG10201913151TA (en) * | 2015-09-09 | 2020-03-30 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Genetic engineering of macrophages for immunotherapy |
US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
CN105695511A (en) * | 2016-04-13 | 2016-06-22 | 中国人民解放军第三军医大学 | Immortalized HFSC (hair follicle stem cell) line and preparation method thereof |
CN105713880A (en) * | 2016-04-20 | 2016-06-29 | 广东艾时代生物科技有限责任公司 | Serum-free culture medium for hematopoietic stem cell in vitro expansion culture and application thereof |
CN106279403B (en) * | 2016-08-16 | 2019-06-11 | 长春市海兰深生物医学技术有限公司 | A kind of composition, kit and method detecting natural lung cancer associated antibodies |
IL281425B (en) | 2016-12-02 | 2022-07-01 | Taiga Biotechnologies Inc | Nanoparticle formulations |
CN106754728B (en) * | 2016-12-30 | 2020-05-15 | 中国人民解放军总医院 | Metanephric mesenchymal cell line and preparation method and application thereof |
FR3068366B1 (en) * | 2017-06-30 | 2023-11-24 | Francais Du Sang Ets | METHOD FOR PRODUCING ERYTHROID PROGENITORS |
KR20200036874A (en) * | 2017-08-03 | 2020-04-07 | 타이가 바이오테크놀로지스, 인코포레이티드 | Methods and compositions for the treatment of cancer |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
US12023357B2 (en) | 2017-10-13 | 2024-07-02 | Hackensack University Medical Center | Rejuvenated aged hematopoietic stem cells and methods of use |
CN107937342B (en) * | 2017-11-06 | 2021-07-06 | 中国人民解放军第四军医大学 | Method for amplifying neural stem cells through endothelial cell-derived exosomes |
CN108070567A (en) * | 2018-01-19 | 2018-05-25 | 皓昇莱生物制药有限公司 | A kind of urine derived cell strain of immortalization and its construction method |
EP3864141A2 (en) * | 2018-10-12 | 2021-08-18 | Reneuron Limited | Induced pluripotent cell comprising a controllable transgene for conditional immortalisation |
GB201902068D0 (en) * | 2019-02-14 | 2019-04-03 | Cambridge Entpr Ltd | Methods of reactivating proliferative capacity non-proliferative tissues |
CN114729324A (en) * | 2019-07-24 | 2022-07-08 | 斯比根公司 | Preparation method and application of immortalized stem cell strain |
CN110622921B (en) * | 2019-09-29 | 2021-06-15 | 江苏大学 | Construction method and application of mouse model with over-expression FoxG1 in Alzheimer disease lesion region |
GB202005494D0 (en) * | 2020-04-15 | 2020-05-27 | Reneuron Ltd | Induced pluripotent cell comprising a contollable transgene for conditional immortalisation |
KR20220057859A (en) | 2020-10-30 | 2022-05-09 | 전상수 | the chargable pen |
CN116419968A (en) | 2020-11-06 | 2023-07-11 | 染色体移入股份公司 | Preparation method of reversible immortalized cells |
CN113444730A (en) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | Screening and constructing method of primary hepatocyte klotho gene transduction stem cells |
JPWO2023277153A1 (en) * | 2021-06-30 | 2023-01-05 | ||
CN113583965A (en) * | 2021-08-05 | 2021-11-02 | 大连干细胞与精准医学创新研究院 | Condition immortalized human neural stem cell-derived cell membrane nano vesicle preparation as well as preparation method and application thereof |
JPWO2023190271A1 (en) | 2022-03-28 | 2023-10-05 |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
WO1986003780A1 (en) * | 1984-12-21 | 1986-07-03 | Techniclone Research Partners I | Method for electrically immortalizing lymphoid cells |
DE3531430A1 (en) | 1985-09-03 | 1987-03-05 | Biotest Pharma Gmbh | METHOD FOR OBTAINING COMPONENTS FROM A LIQUID WITH COMPONENTS PRESENT IN AREAS SEPARATELY SEPARATED |
US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US4900322A (en) | 1986-09-22 | 1990-02-13 | Adams James D | Blood component pooling valve and kit |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5674980A (en) * | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
IL101147A (en) | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
AU781922B2 (en) | 1991-12-17 | 2005-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5289858A (en) | 1991-12-18 | 1994-03-01 | Abbott Laboratories | System for accommodating withdrawal of liquid from a bulk supply |
US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
CA2135642C (en) | 1992-08-21 | 1999-12-14 | James G. Barsoum | Tat-derived transport polypeptides |
US5580760A (en) | 1993-02-22 | 1996-12-03 | The United States Of America As Represented By The Department Of Health And Human Services | FUSE binding protein and cDNA therefor |
JPH09500534A (en) | 1993-07-22 | 1997-01-21 | メルク エンド カンパニー インコーポレーテッド | Expression of human interleukin-1β in transgenic animals |
US5599705A (en) | 1993-11-16 | 1997-02-04 | Cameron; Robert B. | In vitro method for producing differentiated universally compatible mature human blood cells |
JPH09510088A (en) | 1994-03-03 | 1997-10-14 | アレクション・ファーマシューティカル・インク | Final complement inhibitor fusion gene and protein |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6713247B1 (en) * | 1996-09-03 | 2004-03-30 | Signal Pharmaceuticials, Inc. | Human CNS cell lines and methods of use therefor |
AU734827B2 (en) | 1997-05-21 | 2001-06-21 | Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
EP0893493A3 (en) | 1997-07-21 | 2002-12-04 | Aventis Pharma Deutschland GmbH | Genetically modified cells and their use for prophylaxis or treatment of diseases |
GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
WO1999029721A1 (en) | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
JP4271857B2 (en) | 1998-04-08 | 2009-06-03 | 塩野義製薬株式会社 | Isolation of osteoclast precursor cells and induction of differentiation into osteoclasts |
US6835567B1 (en) | 1998-04-14 | 2004-12-28 | Signal Pharmaceuticals, Inc. | PNS cell lines and methods of use therefor |
US6451558B1 (en) | 1998-08-03 | 2002-09-17 | Novartis Ag | Genes in the control of hematopoiesis |
US6913925B1 (en) | 1998-08-12 | 2005-07-05 | Signal Pharmaceuticals Llc | Human mesencephalon cell lines and methods of use therefor |
CA2364690A1 (en) | 1999-02-28 | 2000-10-19 | Washington University | Novel transduction molecules and methods for using same |
AU4070500A (en) | 1999-04-05 | 2000-10-23 | Biocrystal Limited | Assay kits and methods for immune complex-mediated activation involving shed antigens |
US6451601B1 (en) * | 1999-04-12 | 2002-09-17 | Modex Therapeutiques, S.A. | Transiently immortalized cells for use in gene therapy |
US6358739B1 (en) | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
EP1175436B1 (en) * | 1999-04-12 | 2006-10-11 | Heart Biosystems GmbH | Transiently immortalized cells for use in gene therapy |
US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
US7311920B1 (en) | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
CA2390011A1 (en) * | 1999-11-10 | 2001-05-17 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising renilla gfp |
EP1103615A1 (en) | 1999-11-25 | 2001-05-30 | Universite De Geneve | Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
US20010049393A1 (en) | 1999-12-07 | 2001-12-06 | Whitehead Institute For Biomedical Research | Methods for defining MYC target genes and uses thereof |
EP1285577A4 (en) | 2000-05-15 | 2007-05-09 | Sonoko Habu | Chimeric mouse having an immune system constructed with human cd34-positive cells and use thereof |
US20020155127A1 (en) | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
US20070248618A1 (en) | 2004-03-16 | 2007-10-25 | Cohen David I | Tat-Based vaccine Compositions and Methods of Making and Using Same |
ATE428790T1 (en) | 2000-09-25 | 2009-05-15 | Genetronics Inc | IMPROVED SYSTEM FOR REGULATING TRANSGENE EXPRESSION |
CA2427747A1 (en) | 2000-10-30 | 2002-05-10 | Kalobios, Inc. | Affinity maturation by competitive selection |
WO2002036806A2 (en) | 2000-11-01 | 2002-05-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Expression vectors able to elicit improved immune response and methods of using same |
WO2002043477A1 (en) | 2000-12-01 | 2002-06-06 | Central Institute For Experimental Animals | Method of constructing mouse suitable for the take, differentiation and proliferation of heterogenous cells, mouse constructed by this method and use of the mouse |
WO2002057436A2 (en) | 2001-01-19 | 2002-07-25 | Gendel Limited | Red blood cell from a transgenic animal as vehicle for polypeptide delivery |
US7033744B2 (en) | 2001-03-16 | 2006-04-25 | Naoya Kobayashi | Method for proliferating a liver cell, a liver cell obtained thereby, and use thereof |
ATE403676T1 (en) * | 2001-05-31 | 2008-08-15 | Novartis Ag | NEW ESTROGEN RECEPTOR LIGAND BINDING DOMAIN VARIANTS AND NEW LIGANDS AND PHARMACEUTICAL COMPOSITIONS |
US7329731B2 (en) | 2001-08-31 | 2008-02-12 | Medigene Limited | Soluble T cell receptor |
CN1408850A (en) * | 2001-09-18 | 2003-04-09 | 王虹 | Immortal technology for human blood dentritic cell |
CN100506978C (en) | 2001-09-21 | 2009-07-01 | 中国人民解放军军事医学科学院野战输血研究所 | Hemapoietic stem/ancestral cell enriching method and its in vitro directional induction and differentiation |
GB0124391D0 (en) | 2001-10-11 | 2001-11-28 | Gene Expression Technologies L | Control of gene expression |
WO2003039462A2 (en) | 2001-11-02 | 2003-05-15 | Tanox, Inc. | B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies |
EP1321034A1 (en) * | 2001-12-21 | 2003-06-25 | Pfizer Products Inc. | Disruption of the phosphodieterase 10 gene |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
AU2003202908A1 (en) | 2002-01-03 | 2003-07-24 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
US20030216315A1 (en) | 2002-02-13 | 2003-11-20 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
CN1240439C (en) | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | Genetic switch medicine for treating tumor |
US7211191B2 (en) | 2004-09-30 | 2007-05-01 | Thermogenesis Corp. | Blood component separation method and apparatus |
US20030226159A1 (en) | 2002-04-16 | 2003-12-04 | Bachoo Robert M. | Cancer models |
GB2387599B (en) | 2002-04-17 | 2005-08-10 | Jason Peter Brown | Methods for producing antibodies |
EP1504037B1 (en) * | 2002-05-10 | 2009-12-30 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
CN101108882A (en) * | 2002-05-16 | 2008-01-23 | 巴法里安诺迪克有限公司 | Fusion protein of HIV regulatory/accessory proteins |
ES2439874T3 (en) * | 2002-05-29 | 2014-01-27 | Regeneron Pharmaceuticals, Inc. | Induced eukaryotic expression system |
AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
ATE350480T1 (en) | 2002-10-11 | 2007-01-15 | Imvision Gmbh | MODULAR ANTIGEN TRANSPORTER MOLECULES (MAT MOLECULES) FOR MODULATING IMMUNE REACTIONS, ASSOCIATED CONSTRUCTS, METHODS AND USES |
WO2004035535A2 (en) | 2002-10-15 | 2004-04-29 | Yeda Research And Development Co. Ltd. | Erythrocyte differentiation factor, gene encoding same, and methods of use thereof |
AU2003276403B2 (en) | 2002-11-09 | 2010-04-15 | Adaptimmune Limited | T cell receptor display |
JP2006509010A (en) | 2002-12-05 | 2006-03-16 | インペリアル・カレッジ・イノベイションズ・リミテッド | Control of apoptosis |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
WO2004084805A2 (en) | 2003-03-19 | 2004-10-07 | The J. David Gladstone Institutes | Acetylated tat polypeptides and methods of use thereof |
US20040224402A1 (en) | 2003-05-08 | 2004-11-11 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific T cells |
WO2005014785A2 (en) | 2003-06-18 | 2005-02-17 | The George Washington University | Conditionally-immortalized hematopoietic progenitor cell lines |
US20060222657A1 (en) | 2003-06-20 | 2006-10-05 | Dowdy Steven F | Polypeptide transduction and fusogenic peptides |
IL161903A0 (en) | 2003-07-17 | 2005-11-20 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs |
US7705049B2 (en) | 2004-01-21 | 2010-04-27 | New York University | Methods for treating non-melanoma cancers with PABA |
JP2005232148A (en) * | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | Use of propargylamine as neuroprotective agent |
AU2005245664B2 (en) | 2004-05-19 | 2012-02-02 | Adaptimmune Limited | High affinity NY-ESO T cell receptor |
CA2567349C (en) | 2004-05-19 | 2012-11-27 | Avidex Ltd | Method of improving t cell receptors |
EP1791865B1 (en) | 2004-06-29 | 2010-07-28 | Immunocore Ltd. | Cells expressing a modified t cell receptor |
WO2006137836A2 (en) | 2004-08-17 | 2006-12-28 | Research Development Foundation | Bacterial vector systems |
GB0420963D0 (en) | 2004-09-21 | 2004-10-20 | Reneuron Ltd | Hepatocyte |
WO2006045064A2 (en) * | 2004-10-20 | 2006-04-27 | Whitehead Institute For Biomedical Research | Cultured hematopoietic stem cells and method for expansion and analysis thereof |
WO2007067183A1 (en) | 2005-12-09 | 2007-06-14 | The Regents Of The University Of California | Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells |
US20060156422A1 (en) | 2005-01-10 | 2006-07-13 | Medical Research Council | Methods and compositions for the generation of antibodies |
JP2008535823A (en) | 2005-03-25 | 2008-09-04 | キュラジェン コーポレイション | Antibodies against major antigens of tenascin |
WO2006116512A1 (en) | 2005-04-26 | 2006-11-02 | The Board Of Trustees Of The University Of Illinois, Urbana, Il | Nucleoside compounds and methods of use thereof |
WO2006125962A2 (en) | 2005-05-25 | 2006-11-30 | Medigene Limited | T cell receptors which specifically bind to vygfvracl-hla-a24 |
EP2056800B1 (en) | 2005-08-26 | 2015-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
US20070047583A1 (en) | 2005-08-29 | 2007-03-01 | Siemens Aktiengesellschaft | Method for using a short address in a packet header |
CA2626525C (en) | 2005-10-18 | 2020-03-10 | National Jewish Medical And Research Center | Conditionally immortalized long-term stem cells and methods of making and using such cells |
CA2626584A1 (en) | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
EP1792627A1 (en) | 2005-12-05 | 2007-06-06 | ImVisioN AG | Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules |
US8088379B2 (en) | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
EP2087000A2 (en) | 2006-09-29 | 2009-08-12 | Immunocore Ltd. | T cell therapies |
EP2583550A1 (en) | 2007-03-13 | 2013-04-24 | National Jewish Health | Methods for generation of antibodies |
EP2214670A2 (en) | 2007-11-02 | 2010-08-11 | Taiga Biotechnologies, Inc. | Compounds for treating abnormal cellular proliferation |
SG10201808863UA (en) | 2008-03-17 | 2018-11-29 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
KR20170078862A (en) | 2008-05-16 | 2017-07-07 | 타이가 바이오테크놀로지스, 인코포레이티드 | Antibodies and processes for preparing the same |
WO2009149956A2 (en) | 2008-06-13 | 2009-12-17 | Life & Brain Gmbh | Fusion protein and use thereof |
AU2009274172B2 (en) | 2008-07-21 | 2015-08-13 | Htyr Acquisition Llc | Differentiated anucleated cells and method for preparing the same |
EP3339321B1 (en) | 2008-08-28 | 2021-04-28 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same and methods of identifying agents that modulate myc |
CN107523587A (en) | 2008-11-06 | 2017-12-29 | 印第安纳大学研究与技术公司 | Strengthen the material and method of candidate stem cell implantation process |
AU2009317161B2 (en) | 2008-11-24 | 2014-09-11 | Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
WO2011100477A2 (en) | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
US20120107317A1 (en) | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
PL3392270T3 (en) | 2011-09-15 | 2021-03-08 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
EP2844743B1 (en) | 2012-05-03 | 2021-01-13 | Fred Hutchinson Cancer Research Center | Enhanced affinity t cell receptors and methods for making the same |
DE102012209673A1 (en) | 2012-06-08 | 2013-12-24 | Artcline Gmbh | A method for producing a leukocyte preparation and leukocyte preparation |
CN114645015A (en) | 2012-07-20 | 2022-06-21 | 泰加生物工艺学公司 | Enhanced reconstitution and autoreconstitution of hematopoietic compartments |
RU2015106749A (en) | 2012-07-27 | 2016-09-20 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс | CONSTRUCTION OF T-CELL RECEPTORS |
US20140109246A1 (en) | 2012-09-24 | 2014-04-17 | The Regents Of The University Of Colorado, A Body Corporate | Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species |
GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
EP2961415B1 (en) | 2013-03-01 | 2021-01-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
CA2902448C (en) | 2013-03-01 | 2023-04-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor reactive t cells from peripheral blood |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
ES2730325T3 (en) | 2014-04-24 | 2019-11-11 | Univ Texas | Application of induced pluripotent cytoblasts to generate adoptive cell therapy products |
KR20230144092A (en) | 2014-12-24 | 2023-10-13 | 넥스이뮨, 인크. | Nanoparticle compositions and methods for immunotherapy |
AU2017207450B2 (en) | 2016-01-15 | 2021-11-04 | Berkeley Lights, Inc. | Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
-
2006
- 2006-10-18 CA CA2626525A patent/CA2626525C/en active Active
- 2006-10-18 US US11/583,970 patent/US8883507B2/en active Active
- 2006-10-18 IN IN6624DEN2014 patent/IN2014DN06624A/en unknown
- 2006-10-18 CN CN201510760532.XA patent/CN105483088B/en not_active Expired - Fee Related
- 2006-10-18 IL IL296832A patent/IL296832A/en unknown
- 2006-10-18 CA CA3065947A patent/CA3065947C/en active Active
- 2006-10-18 WO PCT/US2006/040379 patent/WO2007047583A2/en active Application Filing
- 2006-10-18 KR KR1020087011791A patent/KR101441693B1/en active IP Right Grant
- 2006-10-18 KR KR1020137028338A patent/KR101441843B1/en active IP Right Grant
- 2006-10-18 CN CN200680045545.8A patent/CN101330830B/en not_active Expired - Fee Related
- 2006-10-18 EP EP06826025A patent/EP1942739B1/en active Active
- 2006-10-18 AT AT06826025T patent/ATE491022T1/en active
- 2006-10-18 AU AU2006304392A patent/AU2006304392B2/en not_active Ceased
- 2006-10-18 IL IL286053A patent/IL286053B2/en unknown
- 2006-10-18 DE DE602006018768T patent/DE602006018768D1/en active Active
- 2006-10-18 JP JP2008536713A patent/JP2009511081A/en active Pending
-
2008
- 2008-04-17 IL IL190946A patent/IL190946A/en active IP Right Grant
-
2009
- 2009-06-22 HK HK09105588.8A patent/HK1126623A1/en not_active IP Right Cessation
- 2009-06-22 HK HK16110996.5A patent/HK1222890A1/en unknown
-
2010
- 2010-02-05 US US12/701,383 patent/US9150831B2/en active Active
-
2012
- 2012-10-03 JP JP2012221023A patent/JP5726148B2/en active Active
-
2013
- 2013-01-30 IL IL224494A patent/IL224494B/en active IP Right Grant
-
2014
- 2014-05-26 JP JP2014108137A patent/JP6302356B2/en active Active
- 2014-10-08 US US14/509,870 patent/US9796961B2/en active Active
-
2015
- 2015-10-02 US US14/873,296 patent/US20160040129A1/en not_active Abandoned
-
2016
- 2016-02-17 JP JP2016027812A patent/JP2016129515A/en active Pending
-
2017
- 2017-08-31 JP JP2017166334A patent/JP6655050B2/en not_active Expired - Fee Related
- 2017-12-24 IL IL256512A patent/IL256512B/en active IP Right Grant
-
2018
- 2018-07-23 US US16/042,904 patent/US10760055B2/en active Active
-
2019
- 2019-01-18 JP JP2019006759A patent/JP6797221B2/en not_active Expired - Fee Related
- 2019-04-14 IL IL266009A patent/IL266009B/en active IP Right Grant
-
2020
- 2020-06-15 US US16/901,956 patent/US20200308545A1/en not_active Abandoned
- 2020-07-10 JP JP2020119082A patent/JP7078673B2/en active Active
- 2020-11-02 IL IL278426A patent/IL278426B/en unknown
-
2022
- 2022-01-27 US US17/586,196 patent/US20220145253A1/en not_active Abandoned
- 2022-02-22 JP JP2022025236A patent/JP2022065146A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE491022T1 (en) | CONDITIONALLY IMMORTALIZED ADULT LONG-TERM STEM CELLS AND METHOD FOR THE PRODUCTION AND USE OF SUCH CELLS | |
MX2009002388A (en) | Use of human cells of myeloid leukaemia origin for expression of antibodies. | |
DE60231708D1 (en) | Somatic pluripotent cells | |
DE602006017833D1 (en) | LIVER Progenitor Cells | |
TW200833692A (en) | Triazolopyridazine protein kinase modulators | |
EP2227725A4 (en) | Clinical applications of neuropsychological pattern analysis and modeling | |
GB2428044A (en) | Method of forming mesenchymal stem cells from embryonic stem cells | |
Lu et al. | Modeling human neurodevelopmental diseases with brain organoids | |
DE602005018981D1 (en) | Process for the preparation of L-cysteine, and L-cysteine-producing microorganism | |
ATE370224T1 (en) | METHOD FOR PRODUCING L-CYSTEIN USING A BACTERIA BELONGING TO THE GENUS ESCHERICHIA | |
DE60319599T8 (en) | METHOD FOR DIFFERENTIATING A MESENCHYME STEM CELL TO A NERVENZELLE AND THE NERVENZELLE CONTAINING PHARMACEUTICAL COMPOSITION AGAINST A NEURODEGENERATIVE DISEASE | |
DE602005025878D1 (en) | METHOD FOR THE PRODUCTION OF HIGHLY SENSITIVE ENDONUCLEASES, NOVEL PREPARATIONS OF NUCLEASES AND THEIR USE | |
SG11201806843UA (en) | Method for producing activated hepatocyte growth factor (hgf) | |
FR2948381B1 (en) | PROCESS FOR OBTAINING MYOFIBROBLASTS | |
GB2464075A (en) | Parthenote-derived stem cells and methods of making and using them | |
DE60234862D1 (en) | PROCESS FOR PRODUCING HUMAN BETA CELL LINES | |
ATE349513T1 (en) | METHOD FOR THE HOMOGENEOUS MASS CULTIVATION OF T-LYMPHOCYTES | |
ATE521571T1 (en) | METHOD FOR PRODUCING DITHIONITE AND ITS USE | |
FR2880803B1 (en) | LYOPHILIZATION OF BROWN ALGAE CELLS, PROCESS FOR OBTAINING AND USES | |
WO2008129560A3 (en) | An in vitro human embryonic model and a method thereof | |
ATE503005T1 (en) | BONE FORMATION COMPOSITION FROM OSTEOBLAST MIXTURE AND BIOMATRIX AND PRODUCTION METHOD THEREOF | |
DE60025036D1 (en) | PROCESS FOR THE BREEDING OF LIABLE ANIMAL CELLS | |
Lomoio et al. | 3D bioengineered neural tissue generated from patient-derived iPSCs develops time-dependent phenotypes and transcriptional features of Alzheimer’s disease | |
CN102234680A (en) | New method for in vitro detecting biologic clock rhythm | |
Stäble et al. | S137 DNA METHYLATION DYNAMICS IDENTIFY LINEAGE-SPECIFIC REGULATION PATTERNS OF HEMATOPOIETIC DIFFERENTIATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1942739 Country of ref document: EP |